| |
| |
|
| Insider
Information: |
Quinn Anthony |
| Relationship: |
|
| City: |
Lexington |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
670,638 |
|
|
Indirect Shares
|
339,132 |
|
|
| Direct
Value |
$330,713 |
|
|
|
Indirect Value
|
$159,963 |
|
|
| Total
Shares |
1,009,770 |
|
|
| Total
Value |
$490,676 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
7
|
0
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
6
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -68.4%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Synageva BioPharma Corp |
GEVA |
EVP, CMO, & Head of R&D |
2015-06-22 |
0 |
|
0 |
Premium* |
|
|
Aeglea Biotherapeutics, Inc. |
AGLE |
President & CEO, Direc... |
2022-03-16 |
550,540 |
2022-03-16 |
266,295 |
Premium* |
|
|
Kaleido Biosciences, Inc. |
KLDO |
Director |
2019-03-04 |
31,603 |
|
0 |
Premium* |
|
|
Generation Bio Co. |
GBIO |
|
2023-12-01 |
88,495 |
2023-12-01 |
72,837 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
74 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GEVA |
Synageva BioPharma Corp |
EVP, CMO & Head of R&D |
• – – |
2015-04-06 |
4 |
OE |
$0.95 |
$228,069 |
D/D |
19,503 |
45,140 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, CMO & Head of R&D |
• – – |
2015-04-06 |
4 |
AS |
$93.76 |
$2,766,201 |
D/D |
(29,503) |
15,637 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, CMO & Head of R&D |
• – – |
2015-04-15 |
4 |
AS |
$105.00 |
$1,050,000 |
D/D |
(10,000) |
15,637 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, CMO & Head of R&D |
• – – |
2015-04-15 |
4 |
OE |
$40.74 |
$407,400 |
D/D |
10,000 |
25,637 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, CMO & Head of R&D |
• – – |
2015-04-21 |
4 |
AS |
$108.00 |
$1,080,000 |
D/D |
(10,000) |
5,637 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, CMO & Head of R&D |
• – – |
2015-04-27 |
4 |
OE |
$1.70 |
$17,000 |
D/D |
10,000 |
15,637 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, CMO & Head of R&D |
• – – |
2015-04-27 |
4 |
AS |
$110.00 |
$1,100,000 |
D/D |
(10,000) |
5,637 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, CMO, & Head of R&D |
• – – |
2015-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
27,000 |
32,637 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, CMO, & Head of R&D |
• – – |
2015-06-22 |
4 |
A |
$78.87 |
$2,997 |
D/D |
38 |
32,675 |
0 |
- |
|
| GEVA |
Synageva BioPharma Corp |
EVP, CMO, & Head of R&D |
• – – |
2015-06-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(32,675) |
0 |
0 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
Director |
– • – |
2016-04-12 |
4 |
B |
$10.00 |
$100,000 |
D/D |
10,000 |
10,000 |
2.39 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
Director |
– • – |
2017-12-01 |
4 |
B |
$4.53 |
$18,578 |
D/D |
4,100 |
14,100 |
2.39 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
Director |
– • – |
2017-12-04 |
4 |
B |
$4.98 |
$39,624 |
D/D |
7,956 |
22,056 |
2.39 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
Director |
– • – |
2017-12-05 |
4 |
B |
$4.93 |
$24,976 |
D/D |
5,065 |
27,121 |
2.39 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
Interim CEO |
• • – |
2017-12-06 |
4 |
B |
$4.92 |
$24,072 |
D/D |
4,888 |
32,009 |
2.81 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
Interim CEO |
• • – |
2017-12-07 |
4 |
B |
$4.99 |
$13,967 |
D/D |
2,800 |
34,809 |
2.81 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
Interim CEO |
• • – |
2017-12-08 |
4 |
B |
$5.07 |
$3,039 |
D/D |
600 |
35,409 |
2.73 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
Interim CEO |
• • – |
2018-02-15 |
4 |
OE |
$5.46 |
$83,052 |
D/D |
15,211 |
50,620 |
0 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
President & CEO |
• • – |
2018-02-15 |
4 |
B |
$6.02 |
$12,040 |
D/D |
2,000 |
94,793 |
2.81 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
Interim CEO |
• • – |
2018-07-11 |
4 |
OE |
$5.46 |
$18,056 |
D/D |
3,307 |
53,927 |
0 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
Interim CEO |
• • – |
2018-07-12 |
4 |
OE |
$6.31 |
$262,764 |
D/D |
38,866 |
92,793 |
0 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
President & CEO |
• • – |
2018-08-15 |
4 |
B |
$9.13 |
$9,075 |
D/D |
994 |
95,787 |
2.81 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
President & CEO |
• • – |
2018-12-07 |
4 |
OE |
$4.11 |
$751,816 |
D/D |
171,890 |
267,677 |
0 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
President & CEO |
• • – |
2019-02-06 |
4 |
OE |
$5.46 |
$54,126 |
D/D |
8,756 |
276,433 |
0 |
- |
|
| AGLE |
Aeglea Biotherapeutics, I... |
President & CEO |
• • – |
2019-02-15 |
4 |
B |
$7.10 |
$5,103 |
D/D |
719 |
277,152 |
2.81 |
- |
|
74 Records found
|
|
Page 2 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
